| Bioactivity | Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer[1][2]. |
| Invitro | Elpamotide shows potent and specific cytotoxicity in cytotoxic T lymphocytes (CTLs) (4-hour 51Cr-release assay) [1]. |
| Name | Elpamotide |
| CAS | 673478-49-4 |
| Shortening | RFVPDGNRI |
| Formula | C47H76N16O13 |
| Molar Mass | 1073.21 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Elpamotide
CAS: 673478-49-4 F: C47H76N16O13 W: 1073.21
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-e
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.